Hepatitis E is an enteric-transmitted liver disease induced by the hepatitis E virus (HEV). This is one of the five human hepatitis viruses that have been identified (A, B, C, D, and E). Hepatitis E is transmitted via fecal-oral contact due to contamination of drinking water with feces. Vertical transmission from a pregnant woman to her baby, transfusion of contaminated blood products, and eating of undercooked meat and/or meat products produced from infected animals are the additional ways of spread of hepatitis E virus. In areas where sanitation is inadequate, hepatitis E virus infections are widespread, which is likely to benefit development of the global hepatitis e diagnostic tests market in the forthcoming years.
πππ πππ¦π©π₯π πππ©π¨π«π πππ : https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16859
Hepatitis E patients are difficult to identify from other kinds of viral hepatitis. As a result, the detection of RNA andΒ antibodiesΒ against HEV can be used to confirm the diagnosis. Indirect tests are the tests conducted to detect the existence of IgG and IgM, while tests for the existence of HEV RNA are called direct tests. The existence of IgM is the primary test for detecting severe infections in patients, which is then validated by RNA testing. If IgG antibodies are present, then the patient has already been infected with the hepatitis E virus.
- Key players operating in the hepatitis E diagnostic tests market include
- altona Diagnostics GmbH
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Biokit S.A.
- Dia.Pro – Diagnostic Bioprobes s.r.l, F. Hoffmann-La Roche Ltd.
- Fast-track diagnostics Ltd.
- Fortress Diagnostics Limited
- Mikrogen GmBH
- MP Biomedicals
- LLC.
- Primerdesign Ltd.
- among others.